RecruitingPhase 3NCT06348576
Phase III Study to Evaluate the Efficacy and Safety of AD-209
A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-209 in Patients With Essential Hypertension
Sponsor
Addpharma Inc.
Enrollment
280 participants
Start Date
May 20, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the efficacy and safety of AD-209
Eligibility
Min Age: 19 Years
Inclusion Criteria2
- Signed informed consent
- Other inclusions applied
Exclusion Criteria2
- Orthostatic hypotension with symptom
- Other exclusions applied
Interventions
DRUGAD-209
PO, Once daily(QD), 8weeks
DRUGAD-2091
PO, Once daily(QD), 8weeks
DRUGAD-209 Placebo
PO, Once daily(QD), 8weeks
DRUGAD-2091 Placebo
PO, Once daily(QD), 8weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06348576
Related Trials
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT0605963898 locations
Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
NCT045056181 location
Mobile Health Program for Rural Hypertension
NCT055469311 location
The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature
NCT050679981 location
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
NCT070837651 location